A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

J. Monk, Bradley; Parkinson, Christine; Cheol Lim, Myong; M. O’Malley, David; Oaknin, Ana; Wilson, Michelle; L. Coleman, Robert; Lorusso, Domenica; Bessette, Paul; Ghamande, Sharad; Christopoulou, Athina; Provencher, Diane; Prendergast, Emily; Demirkıran, Fuat; Mikheeva, Olga; Yeku, Oladapo; Chudecka-Głaz, Anita; Schenker, Michael; D. Littell, Ramey; Safra, Tamar; Chou, Hung‐Hsueh; A. Morgan, Mark; Drochýtek, Vít; N. Barlin, Joyce; Van Gorp, Toon; R. Ueland, Frederick; Lindahl, Gabriel; Anderson, Charles; Catherine Collins, Dearbhaile; N. Moore, Kathleen; Marmé, Frederik; N. Westin, Shannon; A. McNeish, Iain; Shih, Danny; K. Lin, Kevin; Goble, Sandra; Hume, Stephanie; Fujiwara, Keiichi; Kristeleit, Rebecca

doi:10.1200/jco.22.01003

Public

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Published in Journal of Clinical Oncology • Jun 6, 2022

Authors:

Bradley J. Monk

Christine Parkinson

Myong Cheol Lim

Abstract

PURPOSE ATHENA (ClinicalTrials.gov identifier: NCT03522246 ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinica...

Subject

Medicine

Population

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!